Table 1 Demographic, disease features and therapy of patients with giant cell arteritis at disease onset and Takayasu arteritis
Variables | GCA | HC | p | Variables | TA | HC | p |
|---|---|---|---|---|---|---|---|
(n = 18) | (n = 16) | (n = 29) | (n = 29) | ||||
Demographic features | |||||||
Age, years | 72.0 (63.7–75.0) | 68.5 (63.0–72.0) | 0.643 | Age, years | 38.0 (34.5–48.5) | 38.0 (27.5–48.5) | 0.392 |
Females, n (%) | 14 (77.8) | 11 (68.8) | 0.551 | Females, n (%) | 28 (96.6) | 27 (93.1) | 0.553 |
Disease features and therapy | |||||||
GCA | Results | TA | Results | ||||
Headache, n (%) | 12 (66.7) | Disease duration, months | 108 (60–186) | ||||
Constitutional symptoms, n (%) | 8 (44.4) | Angiographic type V, n (%) | 16 (55.2) | ||||
Cranial ischemic manifestations, n (%) | 8 (44.4) | Previous ischemic events, n (%) | 11 (37.9) | ||||
Jaw claudication, n (%) | 6 (33.3) | Active disease, n (%) | 11 (37.9) | ||||
Visual symptoms, n (%) | 4 (22.2) | Remission, n (%) | 18 (62.1) | ||||
Polymyalgia rheumatica, n (%) | 4 (22.2) | Statins, n (%) | 16 (55.2) | ||||
Headache, n (%) | 12 (66.7) | Prednisone, n (%) | 16 (55.2) | ||||
ESR, mm/1st hour | 69.6 ± 28.7 | Prednisone daily dose, mg | 8.7 (5.0–28.7) | ||||
CRP, mg/l | 40.0 (20.2–84.2) | Immunosuppressive agents, n (%) | 19 (65.5) | ||||
Positive TAB, n/total | 8/11 | Biological agents, n (%) | 9 (31.0) | ||||
Positive PET-CT scan, n/total | 13/15 | ||||||